These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2226975)

  • 21. Cardiovascular therapeutics.
    Shakur R; Cockrum E; Scott D
    Br J Hosp Med (Lond); 2008 Sep; 69(9):M136-40. PubMed ID: 18819300
    [No Abstract]   [Full Text] [Related]  

  • 22. Hypothyroidism and cardiovascular disease.
    Nichols N
    Can J Cardiovasc Nurs; 2005; 15(4):68-73; quiz 73, 68. PubMed ID: 16350391
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiovascular pharmacology of aging.
    Podrazik PM; Schwartz JB
    Cardiol Clin; 1999 Feb; 17(1):17-34. PubMed ID: 10093763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of drug discovery for treatment of cardiovascular diseases.
    Kennedy C
    Future Med Chem; 2013 Mar; 5(4):355-7. PubMed ID: 23495678
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular pharmacogenetics.
    Myburgh R; Hochfeld WE; Dodgen TM; Ker J; Pepper MS
    Pharmacol Ther; 2012 Mar; 133(3):280-90. PubMed ID: 22123178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translating molecular target into drug therapy in cardiovascular disease.
    Bril A; Avkiran M
    Curr Opin Pharmacol; 2008 Apr; 8(2):111-3. PubMed ID: 18294914
    [No Abstract]   [Full Text] [Related]  

  • 27. Adverse drug reactions in patients with cardiovascular disease.
    Faulx MD; Francis GS
    Curr Probl Cardiol; 2008 Dec; 33(12):703-68. PubMed ID: 19000586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P450-mediated cardiovascular drug interactions.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1065-82. PubMed ID: 21810031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular pharmacology in the post-blockbuster era.
    Brandes RP
    Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904
    [No Abstract]   [Full Text] [Related]  

  • 30. [Chronobiology and chronopharmacology of cardiovascular diseases].
    Lemmer B
    Wien Med Wochenschr; 1995; 145(17-18):445-7. PubMed ID: 8588361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sex differences and cardiovascular drugs].
    Løchen ML; Kvan E
    Tidsskr Nor Laegeforen; 2010 Feb; 130(4):382-4. PubMed ID: 20220863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug therapy of cardiovascular diseases in the elderly].
    Kuprash LP
    Med Sestra; 1983 Jan; 42(1):23-6. PubMed ID: 6550159
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.
    Brass EP; Lewis RJ; Lipicky R; Murphy J; Hiatt WR
    Clin Pharmacol Ther; 2006 Mar; 79(3):165-72. PubMed ID: 16513441
    [No Abstract]   [Full Text] [Related]  

  • 34. Heart and mind: (2) psychotropic and cardiovascular therapeutics.
    Shah SU; Iqbal Z; White A; White S
    Postgrad Med J; 2005 Jan; 81(951):33-40. PubMed ID: 15640426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adequate dose--that is the solution. Discussion of article by J. Spácil: Maximal or medium drug doses in cardiovascular diseases?].
    Jerie P
    Vnitr Lek; 2003 Oct; 49(10):820-1; author reply 822-3. PubMed ID: 14735892
    [No Abstract]   [Full Text] [Related]  

  • 36. Between a rock and a hard place.
    Demaria AN
    J Am Coll Cardiol; 2010 Nov; 56(21):1761-2. PubMed ID: 21070930
    [No Abstract]   [Full Text] [Related]  

  • 37. Share your herbal supplement use with your doctor. Research shows that some popular supplements may be dangerous for people with cardiovascular diseases.
    Heart Advis; 2010 Apr; 13(4):6-7. PubMed ID: 23043208
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction.
    Izzo AA; Di Carlo G; Borrelli F; Ernst E
    Int J Cardiol; 2005 Jan; 98(1):1-14. PubMed ID: 15676159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What happened to the polypill?
    Watts G
    BMJ; 2008 Sep; 337():a1822. PubMed ID: 18819953
    [No Abstract]   [Full Text] [Related]  

  • 40. Genomics-based cardiovascular drug development: the challenges are just beginning.
    Mucke HA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):203-5. PubMed ID: 16555679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.